Last update:
Clinical pharmacology news
Drug apitegromab may stop muscle loss when taking weight loss drugs
A drug called apitegromab may help preserve lean body mass during weight loss with tirzepatide, a GLP-1 receptor agonist, according to a phase 2 clinical trial published in Nature Medicine. The findings suggest that blocking ...
20 hours ago
0
4
Key protein behind chemotherapy resistance in colorectal cancer identified
One of the most widely used chemotherapeutic agents for colorectal cancer is 5-fluorouracil (5-FU), a cornerstone treatment that has improved outcomes for countless patients. However, repeated treatment often leads to drug ...
13 hours ago
0
1
Single high dose of psilocybin temporarily restores lost abilities in an 80-year-old Alzheimer's patient
Psilocybin is a naturally occurring psychoactive compound found in mushrooms of the Psilocybe genus. These mushrooms may have existed on Earth for nearly 65 million years, dating to the asteroid impact that caused the dinosaurs' ...
New GLP-3 drug significantly slashes both weight and blood sugar levels in Phase III trial
Over the past few years, GLP-1 drugs have transformed the treatment landscape for obesity and type 2 diabetes. By mimicking a hormone that helps regulate blood sugar, slows digestion and curbs appetite, these medications ...
Physician–researcher's work yields landmark five-year data for Crohn's disease drug
A physician–scientist and national leader in inflammatory bowel disease at the University of Cincinnati has led the publication of landmark five-year efficacy and safety data for guselkumab, a biologic therapy for moderately ...
22 hours ago
0
4
Tiny molecular fix revived tuberculosis antibiotic candidate and led to two patents
How can we combat the growing global health crisis of antibiotic resistance? At Leiden University, researchers are tackling this issue from multiple angles. Ph.D. candidate Vladyslav Lysenko develops and redesigns new antibiotic ...
23 hours ago
0
3
Medication burden and weight loss linked to fracture, fall risk in older adults
With an aging population now an irrefutable reality in Japan, concerns about the health and well-being of older adults have come to the forefront of public health dialogue. Older adults are especially at risk for fragility ...
23 hours ago
0
2
A popular joint pain supplement may accelerate dementia
New research has found an association between taking glucosamine, a popular over-the-counter supplement used for joint pain, and a higher likelihood of progressing from mild cognitive impairment to Alzheimer's disease. The ...
Jun 9, 2026
0
316
New Lassa fever vaccine shows promising results for first-in-human clinical trial
Researchers at the University of Maryland School of Medicine's Center for Vaccine Development and Global Health, or CVD, report encouraging results from an early clinical trial that tested a new dual vaccine against Lassa ...
Jun 9, 2026
0
6
Encouraging trial results for AstraZeneca's new weight-loss pill
A new pill developed by the British pharmaceutical firm AstraZeneca appears to help people lose a similar amount of weight as other oral GLP-1 drugs, trial results showed Monday.
Jun 9, 2026
0
6
Ultrasound turns anticancer molecule into deep-lung bacteria killer
An anticancer medication called TLD1433, a ruthenium(II) complex that has entered Phase II trials for conditions such as non-muscle-invasive bladder cancer, is now being repurposed to address one of the biggest public health ...
New GLP-1 oral pill lowers blood sugar and reduces bodyweight, clinical trial finds
Oral GLP-1 medications have the potential to increase access to therapies that can help lower blood sugar and reduce bodyweight. At the American Diabetes Association's Scientific Session, Mass General Brigham physician investigator ...
Jun 8, 2026
0
25
New drug could slow the development of Alzheimer's
"Compound 10" is how Ursula Quitterer refers to the chemical compound that her team has developed and that could slow the progression of Alzheimer's disease. Quitterer is a professor of molecular pharmacology at ETH Zurich ...
Jun 8, 2026
0
14
Left-handed DNA tubes double cancer drug killing by boosting cell uptake
Researchers in the lab of Cancer Center at Illinois (CCIL) member Xing Wang have discovered the influential role of structural chirality, or "handedness," of a DNA nanostructure to dictate cancer cell response to targeted ...
Jun 8, 2026
0
6
New map reveals how antidepressants reshape the brain's serotonin system
A new study has uncovered how antidepressants affect different groups of serotonin-producing brain cells in opposite ways, offering new insights into why selective serotonin reuptake inhibitors (SSRIs) can cause unpleasant ...
Jun 8, 2026
0
9
Africa races for Ebola vaccine as outbreak outpaces response
Researchers racing to develop a vaccine to fight the growing Ebola outbreak centered in the Democratic Republic of the Congo (DRC) say doses could be ready for human testing within "two to three months," while the more promising ...
Jun 8, 2026
0
7
Ozempic, GPL-1s may help curb substance use disorders, study finds
A new study led by researchers at the University of Texas at El Paso found that use of weight-loss drugs like Ozempic and other GLP-1s is associated with a lower risk of developing alcohol, opioid, nicotine and cocaine use ...
Jun 8, 2026
0
5
Nanoparticles target psoriasis genes, aiming to treat 190 million people worldwide
A technological platform developed by Brazilian researchers could revolutionize the treatment of skin diseases such as psoriasis and vitiligo. The group, affiliated with the NanoGeneSkin laboratory at the University of São ...
Jun 8, 2026
0
3
The hunt for a new Ebola vaccine: Two scientists explain the challenges
The ongoing Ebola virus outbreak in the Democratic Republic of Congo (DRC) and Uganda has now killed 61 people, with 359 confirmed cases. The Bundibugyo strain of the virus has a fatality rate of between 30% and 50%, and ...
Jun 8, 2026
0
3
Hay fever, antihistamines and the evidence on dementia risk
For millions of people around the world, pollen season means weeks of sneezing, itchy eyes, and a blocked or runny nose. The timing varies depending on where you live and which plants are in flower, but grass pollen is one ...
Jun 8, 2026
0
7
Target trial does not suggest major adverse outcomes with early GLP-1 use in pregnancy
A target trial emulation estimated the risks associated with glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure in early pregnancy. The findings did not indicate a substantially increased risk for nonlive birth, ...
Jun 8, 2026
0
4
Study proposes reconsidering how histone deacetylase inhibitors work in cancer treatment
Researchers at Baylor College of Medicine and collaborating institutions are challenging the traditional understanding of how cancer drugs called histone deacetylase (HDAC) inhibitors function. For decades, scientists believed ...
Jun 7, 2026
0
13
Antibody fragment prevents hemorrhages associated with new Alzheimer's treatments
In 2025, the European Medicines Agency approved two antibodies for Alzheimer's disease: lecanemab (LeqembiTM, from Biogen) and donanemab (Kisunla, from Eli Lilly and Co.), both based on immunotherapy (the use of molecules ...
Jun 6, 2026
0
10
Drug nearly doubles survival in advanced pancreatic cancer—how daraxonrasib overcame an 'undruggable' disease
For a long time, the likelihood of surviving pancreatic cancer has been extremely low. For patients who were diagnosed with metastatic pancreatic cancer between 2015 and 2021, about 97% died within five years of their diagnosis.
Jun 6, 2026
0
13
GLP-1-based meds are linked to fewer heart events in adults with obesity, autoimmune disease
Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) medication had lower rates of emergency department visits and were less likely to experience serious ...
Jun 6, 2026
0
8
